Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Peterlabs Holdings BhdXKLS:0171 47 Cyclically Adjusted PB Ratio is 0.79 as of Jul. 21, 2026. GuruFocus rates XKLS:0171 with a GF Score™ of 47/100. Among 757 Drug Manufacturers companies, Peterlabs Holdings Bhd ranks better than 76.49% on this metric.
The historical rank and industry rank for Peterlabs Holdings Bhd's Cyclically Adjusted PB Ratio or its related term are showing as below:
XKLS:0171's Cyclically Adjusted PB Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.86 * Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Peterlabs Holdings Bhd's adjusted book value per share data for the three months ended in Jun. 2025 was RM0.279. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is RM0.29 for the trailing ten years ended in Jun. 2025.
Shiller PE for Stocks: The True Measure of Stock Valuation
Peterlabs Holdings Bhd (XKLS:0171) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Peterlabs Holdings Bhd Cyclically Adjusted PB Ratio Related Terms
Peterlabs Holdings Bhd Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for Peterlabs Holdings Bhd's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Peterlabs Holdings Bhd Cyclically Adjusted PB Ratio Chart
XKLS:0171 vs ZTS, UTHR, VTRS: Cyclically Adjusted PB Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Peterlabs Holdings Bhd's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Peterlabs Holdings Bhd Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Peterlabs Holdings Bhd's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Peterlabs Holdings Bhd's Cyclically Adjusted PB Ratio falls into.
Peterlabs Holdings Bhd Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 0.79 mean?
Peterlabs Holdings Bhd (XKLS:0171) has a Cyclically Adjusted PB Ratio of 0.79 as of Jul. 21, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Peterlabs Holdings Bhd and its competitors. According to the industry distribution chart, Peterlabs Holdings Bhd ranks #178 out of 757 companies in the Drug Manufacturers industry, placing it in the top 23.5%.
Is Peterlabs Holdings Bhd's Cyclically Adjusted PB Ratio too high?
Peterlabs Holdings Bhd's current Cyclically Adjusted PB Ratio is 0.79. The Drug Manufacturers industry median Cyclically Adjusted PB Ratio is 1.86. Peterlabs Holdings Bhd's value of 0.79 is 57.5% below this industry median. Based on the distribution chart, Peterlabs Holdings Bhd ranks #178 out of 757 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Peterlabs Holdings Bhd has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Peterlabs Holdings Bhd's Cyclically Adjusted PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Peterlabs Holdings Bhd ranks #178 out of 757 companies for Cyclically Adjusted PB Ratio. This places Peterlabs Holdings Bhd in the top 24% of its industry — outperforming the majority of peers. The industry median Cyclically Adjusted PB Ratio is 1.86. Peterlabs Holdings Bhd's value of 0.79 is 57.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Drug Manufacturers company?
The median Cyclically Adjusted PB Ratio among Drug Manufacturers companies is 1.86, based on 757 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Peterlabs Holdings Bhd's current Cyclically Adjusted PB Ratio of 0.79 is 57.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Peterlabs Holdings Bhd and its competitors. For the Drug Manufacturers industry, the median Cyclically Adjusted PB Ratio is 1.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Peterlabs Holdings Bhd's current Cyclically Adjusted PB Ratio is 0.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Peterlabs Holdings Bhd stock overvalued right now?
Peterlabs Holdings Bhd (XKLS:0171) has a current Cyclically Adjusted PB Ratio of 0.79. The current Cyclically Adjusted PB Ratio is 0.79 and 57.5% below the Drug Manufacturers industry median of 1.86. Peterlabs Holdings Bhd's overall GF Score™ is 47/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Peterlabs Holdings Bhd (XKLS:0171), the current Cyclically Adjusted PB Ratio is 0.79 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Peterlabs Holdings Bhd is engaged in the manufacturing, distribution, export, and trading of animal health and nutrition products. The Group offers biosecurity and disinfectants, compound feed supplements, feed additives, nutritional premixes, pharmaceuticals, and water-soluble supplements, as well as farm management, technical advisory services, raw material analysis, and feed formulation. Its segments are Manufacturing, which covers the manufacturing and distribution of animal health and nutrition products; Trading, which involves the trading and distribution of animal health and nutrition products and consumer goods, and contributes the majority of its revenue; and Others, which provides investment holding services. The company operates in Malaysia and internationally.
47GF Score
Get the complete analysis for XKLS:0171
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:0171 has been successfully added to your 
